The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jong-Il | - |
dc.contributor.author | Cho, Dong-Hwan | - |
dc.contributor.author | Hahn, Sang Woo | - |
dc.contributor.author | Jeong, Bumseok | - |
dc.contributor.author | Kim, Jong-Hoon | - |
dc.contributor.author | Kim, Sung-Wan | - |
dc.contributor.author | Koo, Min-Seong | - |
dc.contributor.author | Lee, Seung Hwan | - |
dc.contributor.author | Lee, Seung Jae | - |
dc.contributor.author | Lee, Yo Han | - |
dc.contributor.author | Park, Jong-Ik | - |
dc.contributor.author | Rho, Seung Ho | - |
dc.contributor.author | Chung, Young-Chul | - |
dc.date.available | 2020-02-28T17:47:03Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2014-03 | - |
dc.identifier.issn | 0268-1315 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12804 | - |
dc.description.abstract | We investigated the efficacy and safety of aripiprazole in first-episode psychosis and explored the association between early response and later response to this medication. This was a 6-week, open-label, multicenter trial. The study population consisted of 59 patients with a DSM-IV diagnosis of a schizophreniform disorder, schizoaffective disorder, schizophrenia, or psychotic disorder not otherwise specified. The primary outcome measures were the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression-Severity scale. To assess the safety, we measured the drug-related adverse events, weight, and lipid-related variables. The sensitivity, specificity, positive predictive value, and negative predictive value were calculated for the response status at weeks 2 and 3 to predict the subsequent response at week 6. Among the 59 participants, 38 were able to complete the 6-week trial. Treatment with aripiprazole resulted in significant improvement in the PANSS and Clinical Global Impression scores over time. The response rate (defined as a 30% decrease in the PANSS total score from baseline to the last observation) was 69.1%. The most accurate prediction of later response in terms of negative predictive value and specificity was a reduction in the PANSS total score from baseline to week 3 of at least 20%. Aripiprazole had a modest side effect burden and was characterized by a safe profile with respect to weight and metabolic side effects. These results indicate that aripiprazole is effective and safe in the treatment of first-episode psychosis. The response at week 3, rather than week 2, predicted the later response more accurately. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.relation.isPartOf | INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY | - |
dc.subject | SCHIZOAFFECTIVE DISORDER | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | 2ND-GENERATION ANTIPSYCHOTICS | - |
dc.subject | ACUTE SCHIZOPHRENIA | - |
dc.subject | ONSET HYPOTHESIS | - |
dc.subject | DELAYED-ONSET | - |
dc.subject | SHORT-TERM | - |
dc.subject | HALOPERIDOL | - |
dc.subject | RISPERIDONE | - |
dc.subject | TRIAL | - |
dc.title | The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000331276000002 | - |
dc.identifier.doi | 10.1097/YIC.0000000000000005 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, v.29, no.2, pp.77 - 85 | - |
dc.identifier.scopusid | 2-s2.0-84895077130 | - |
dc.citation.endPage | 85 | - |
dc.citation.startPage | 77 | - |
dc.citation.title | INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY | - |
dc.citation.volume | 29 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Kim, Jong-Hoon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | aripiprazole | - |
dc.subject.keywordAuthor | early response | - |
dc.subject.keywordAuthor | efficacy | - |
dc.subject.keywordAuthor | first-episode psychosis | - |
dc.subject.keywordAuthor | safety | - |
dc.subject.keywordPlus | SCHIZOAFFECTIVE DISORDER | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | 2ND-GENERATION ANTIPSYCHOTICS | - |
dc.subject.keywordPlus | ACUTE SCHIZOPHRENIA | - |
dc.subject.keywordPlus | ONSET HYPOTHESIS | - |
dc.subject.keywordPlus | DELAYED-ONSET | - |
dc.subject.keywordPlus | SHORT-TERM | - |
dc.subject.keywordPlus | HALOPERIDOL | - |
dc.subject.keywordPlus | RISPERIDONE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.